Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Exposure to Remicade (Infliximab) During Pregnancy in Patients With Inflammatory Bowel Disease, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis and Psoriasis: a Review and Analysis of Birth Outcomes From the Swedish, Danish and Finnish Medical Birth Registers

NCT00658827 is registered in ClinicalTrials.gov with Janssen Biotech, Inc. as lead sponsor.

NCT NCT00658827
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00658827 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Exposure to Remicade (Infliximab) During Pregnancy in Patients With Inflammatory Bowel Disease, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis and Psoriasis: a Review and Analysis of Birth Outcomes From the Swedish, Danish and Finnish Medical Birth Registers
Lead sponsor
Janssen Biotech, Inc.
Phase
Observational
Overall status
Completed
Start date
January 1, 2007
Completion date
September 30, 2016
Enrollment
370 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

inflammatory bowel disease